FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

Innate Pharma continues its slow rollout of promising clinical candidates, with 2025 set for key milestones. Read more about IPHA stock here.

LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...

Century Therapeutics, Inc. (NASDAQ: IPSC) outlined a strategic pipeline re-prioritization and shared its financial results ...